Human Islet Amyloid Polypeptide (hIAPP): What It Is and Why It Matters in Diabetes

Human islet amyloid polypeptide (hIAPP), also called amylin, is a 37-amino-acid hormone made by the beta cells of the pancreas and released together with insulin. In type 2 diabetes, hIAPP can misfold and stack into amyloid fibrils inside the pancreatic islets, a change researchers link to beta-cell stress and loss. It is a normal hormone rather than a toxin, and how much it contributes to islet amyloid polypeptide diabetes appears to vary from person to person.

What Is Human Islet Amyloid Polypeptide?

hIAPP is encoded by the IAPP gene on chromosome 12 and is stored in the same secretory granules as insulin. After a meal, both hormones enter the bloodstream together.

• Size: 37 amino acids, which places it firmly in peptide territory.
• Source: pancreatic beta cells.
• Normal jobs: slows gastric emptying, promotes fullness, and helps suppress glucagon release.
• Sequence quirk: residues 20–29 form the sticky region that drives aggregation in humans.

Species matter here. Rats and mice carry proline substitutions in that region, so rodent IAPP does not readily form amyloid — one reason animal models of type 2 diabetes do not tell the whole story. Because it is only 37 residues long, human IAPP is a standard example when textbooks compare polypeptide vs protein.

In the research literature, the label islet amyloid polypeptide iapp is used interchangeably with amylin and hIAPP, depending on whether the human sequence is being specified.

How hIAPP Forms Amyloid Fibrils

Aggregation is a stepwise process. The peptide starts as soluble monomers, then clusters into small oligomers, and eventually assembles into long, insoluble fibrils.

1. Monomers: the normal, functional hormone.
2. Oligomers: small clusters that appear to be the most damaging form because they can disrupt cell membranes.
3. Fibrils: the mature amyloid deposits seen under a microscope in islet tissue.

The intermediate oligomer stage is what most scientists suspect does the harm, since membrane damage and ER stress can push beta cells toward apoptosis. That distinction matters, because the visible amyloid plaque may be more a marker of the process than its direct cause.

One reason hIAPP behaves this way is its polypeptide structure: a short chain with a hydrophobic stretch that encourages stacking, unlike larger folded proteins that bury such regions inside.

Human IAPP Compared With Insulin and Pramlintide

It helps to see how hIAPP compares with the two molecules closest to it clinically.

Feature	Human IAPP (amylin)	Insulin	Pramlintide (Symlin)
Source	Pancreatic beta cells	Pancreatic beta cells	Synthetic amylin analog
Amino acids	37	51, two chains	37, with proline substitutions
Primary role	Gastric emptying, satiety, glucagon suppression	Glucose uptake	Same as amylin
Forms amyloid	Yes, readily	No	Much less
Regulatory status	Endogenous hormone, not a drug	FDA-approved medication	FDA-approved medication

Pramlintide exists precisely because native human IAPP aggregates too easily to be used as a medicine. Swapping in three prolines keeps the hormone's effects on blood sugar and appetite while sharply reducing fibril formation, which is a common theme across polypeptide examples in drug development.

The Diabetes Connection

Islet amyloid is found in the pancreas of roughly 90% of people with type 2 diabetes at autopsy, compared with a much smaller share of people without the disease. The deposits sit between beta cells and often track with reduced insulin secretion.

Several lines of evidence support a real contribution:

• Human IAPP transgenic rodents develop islet amyloid and beta-cell failure, while rodents with the non-aggregating sequence do not.
• Oligomers damage cell membranes in laboratory studies at low concentrations.
• Amyloid deposition appears in transplanted islets and is linked to graft dysfunction over time.

That said, type 2 diabetes is multifactorial. Insulin resistance, chronic inflammation, lipotoxicity, and genetics all play roles, and hIAPP aggregation is one strand in that web rather than the single cause. Some researchers also examine the peptide in type 1 diabetes and islet transplantation, though the evidence there is thinner.

Is hIAPP a Treatment Target?

No therapy is approved to stop hIAPP aggregation in people. Research is active in several directions:

• Aggregation inhibitors: polyphenols such as epigallocatechin gallate, small molecules, and designed peptides that block the sticky 20–29 region.
• Antibodies and chaperones: biologics intended to clear oligomers before they cause damage.
• Gene and sequence approaches: lowering IAPP expression or shifting the ratio of IAPP to insulin.

Broader peptide drug development faces familiar hurdles, and the same delivery problems that affect polypeptide antibiotics — short half-life, poor oral absorption, injection-only dosing — apply to any amylin-directed therapy. Pramlintide itself must be injected and is used with mealtime insulin under medical supervision.

Safety and What This Means for Patients

Human IAPP is not sold as a supplement, and no over-the-counter product can meaningfully change how it behaves in the pancreas. Anyone marketing an "amylin blocker" or "amyloid cleanser" for diabetes should be treated with skepticism.

Pramlintide is a prescription drug. Known risks include hypoglycemia when combined with insulin, nausea, vomiting, and injection-site reactions, and it is not appropriate for everyone. If you have type 2 diabetes and want to know whether amylin-based therapy is relevant to you, that conversation belongs with your clinician.

Scientists keep studying human islet amyloid polypeptide because it sits at the crossroads of protein misfolding and metabolic disease. Understanding how a normal hormone turns into amyloid could inform diabetes care and, more broadly, how the body handles misfolded peptides in other conditions.

COMMON QUESTIONS

Frequently Asked Questions

What is human islet amyloid polypeptide (hIAPP)?

Human islet amyloid polypeptide, also called amylin, is a 37-amino-acid hormone produced by pancreatic beta cells and released alongside insulin. It helps slow stomach emptying, supports a feeling of fullness, and suppresses glucagon. In humans, part of its sequence is prone to misfolding into amyloid fibrils.

Does human islet amyloid polypeptide cause type 2 diabetes?

hIAPP is not considered the single cause of type 2 diabetes, which is a multifactorial disease involving insulin resistance, inflammation, and genetics. However, islet amyloid deposits are found in about 90% of people with type 2 diabetes at autopsy, and hIAPP oligomers can damage beta cells in laboratory studies. Most researchers view the peptide as one contributor to beta-cell decline rather than the root cause.

Is pramlintide the same as human islet amyloid polypeptide?

No. Pramlintide is a synthetic amylin analog with three proline substitutions that reduce its tendency to form amyloid, while human IAPP is the naturally occurring hormone. Pramlintide is FDA-approved and injected with mealtime insulin under medical supervision. Native human IAPP is not an approved drug.